Literature DB >> 16152709

Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals.

Mariana Gerschenson1, Bruce Shiramizu, Daniel E LiButti, Cecilia M Shikuma.   

Abstract

Mitochondrial dysfunction has been demonstrated in subcutaneous adipose tissue from lipoatrophic HIV-1-infected patients treated with nucleoside reverse transcriptase inhibitors (NRTIs). To further assess mitochondrial toxicity, mitochondrial DNA (mtDNA) copies/cell were measured in subcutaneous fat from various sites. Peripheral adipose tissues were obtained from the abdominal wall near the umbilicus, anterior lateral thigh, and dorsal cervical region of the neck of individuals from four cohorts: 1) seven lipoatrophic HIV-1-infected patients receiving a regimen with nucleoside reverse transcriptase inhibitors (NRTIs) as part of highly active antiretroviral therapy (HAART) for > 6 months; 2) seven non-lipoatrophic HIV-1-infected patients receiving NRTIs-containing HAART; 3) five HIV-1-infected patients on antiretroviral therapy < 2 weeks (naive); 4) and five HIV-1-negative participants. Along with the adipose tissue samples, peripheral blood mononuclear cells (PBMC) were also obtained from each patient for mtDNA depletion examination. Total DNA was isolated and mtDNA copies/cell quantitated by competitive and real-time PCR. MtDNA copies/cell in abdomen, thigh, and neck fat were depleted in lipoatrophic HIV-1 seropositive compared to the seropositive naive and seronegative cohorts. MtDNA copies/cell in thigh and neck fat were also decreased in non-lipoatrophic subjects exposed to NRTIs compared with NRTI-naive and HIV seronegative controls. PBMC values did not differ among the cohorts and there was no correlation with lipoatrophy state or HIV-1 serostatus. Additionally, differences in mtDNA copies/cell were observed in the fat depots from seronegative subjects. Thigh fat mtDNA levels were 45-55% lower than abdomen and neck. These studies help demonstrate that mtDNA levels can vary in different subcutaneous adipose depots suggesting possible metabolic differences.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16152709

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  21 in total

1.  Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.

Authors:  Marilyn J Crain; Miriam C Chernoff; James M Oleske; Susan B Brogly; Kathleen M Malee; Peggy R Borum; William A Meyer; Wendy G Mitchell; John H Moye; Heather M Ford-Chatterton; Russell B Van Dyke; George R Seage Iii
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

3.  HIV and mitochondria: more than just drug toxicity.

Authors:  Todd Hulgan; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

4.  Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.

Authors:  Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

5.  HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue.

Authors:  Caryn G Morse; Joachim G Voss; Goran Rakocevic; Mary McLaughlin; Carol L Vinton; Charles Huber; Xiaojun Hu; Jun Yang; Da Wei Huang; Carolea Logun; Robert L Danner; Zoila G Rangel; Peter J Munson; Jan M Orenstein; Elisabeth J Rushing; Richard A Lempicki; Marinos C Dalakas; Joseph A Kovacs
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

6.  Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy.

Authors:  Todd Hulgan; Rebecca T Levinson; Mariana Gerschenson; Nittaya Phanuphak; Jintanat Ananworanich; Nipat Teeratakulpisarm; Tanate Jadwattanakul; Daniel E LiButti; Heidi Fink; Justin C McArthur; Gigi J Ebenezer; Peter Hauer; Deborah Murdock; Cecilia M Shikuma; David C Samuels
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

7.  Subcutaneous Adipocyte Adenosine Triphosphate Levels in HIV Infected Patients.

Authors:  Greg S Gojanovich; Cecilia M Shikuma; Cris Milne; Daniel E Libutti; Dominic C Chow; Mariana Gerschenson
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-17       Impact factor: 2.205

8.  Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy.

Authors:  Tanvi S Sharma; Denise L Jacobson; Lynn Anderson; Mariana Gerschenson; Russell B Van Dyke; Elizabeth J McFarland; Tracie L Miller
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09       Impact factor: 2.205

9.  Subjective clinical lipoatrophy assessment correlates with DEXA-measured limb fat.

Authors:  Marisa Tungsiripat; Mary Ann O'Riordan; Norma Storer; Danielle Harrill; Jason Ganz; Daniel Libutti; Mariana Gerschenson; Grace A McComsey
Journal:  HIV Clin Trials       Date:  2009 Sep-Oct

Review 10.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.